Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9072783 | 0.98 | GCK (0.41) | USP30GRNSORT1GCKCTSS | |
| SCHEMBL9072837 | 0.90 | GCK (0.37) | USP30GRNSORT1GCKCTSS | |
| SCHEMBL2669295 | 0.90 | KMT2A (0.45) | USP30GRNSORT1CTSSCNR2 | |
| SCHEMBL12201410 | 0.89 | USP30 (0.41) | USP30GRNSORT1CTSSCNR2 | |
| SCHEMBL2514653 | 0.80 | CTSS (0.47) | USP30GRNSORT1CTSSCNR2 | |
| SCHEMBL2514651 | 0.80 | CTSS (0.47) | USP30GRNSORT1CTSSCNR2 | |
| SCHEMBL2669226 | 0.76 | CTSL (0.47) | USP30GRNSORT1CTSSCNR2 | |
| SCHEMBL31161053 | 0.74 | CNR2 (0.47) | CTSSCNR2CTSLCTSBCTSK | |
| SCHEMBL9072838 | 0.73 | ALDH1A1 (0.43) | — | |
| SCHEMBL9072851 | 0.70 | GRN (0.43) | USP30GRNSORT1GCKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | USP30 4005/4885GRN 1509/4885SORT1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.